Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing data science and human science together to advance human health and support the pharmaceutical industry from clinical trials to commercialization.
Learn MoreConnecting with powerful, evidence-based market insights to drive agile thinking, uncover growth potential, and gain competitive advantage in this fast-moving consumer health market.
LEARN MOREEmpowering to orchestrate operations across the entire product lifecycle, from concept-to-market, providing quality control, regulatory, safety and compliance solutions along the way.
Learn moreWorking across the health system to address key barriers to deliver high-quality, cost-effective care while improving health outcomes using our data-driven and population-centric solutions.
LEARN MOREDelivering a wide range of consulting and technology solutions to support healthcare stakeholders to drive operational efficiency, enhance quality of patient care, and improve systemic outcomes.
learn moreClinical development enabled by Connected Intelligence™ which combines data and analytics with deep therapeutic and operational expertise to improve efficiency, enhance precision, and bring therapies to patients faster.
Learn MoreHarness the power of real-world data and insights to demonstrate value-driven evidence and outcomes to meet stakeholder needs across the healthcare ecosystem and to propel healthcare forward.
LEARN MOREPharmaceutical market data and information assets that provide actionable data points to help organizations make intelligent connections and drive healthcare forward.
LEARN MOREPrimary Intelligence integrates purpose-built and syndicated research solutions with our wide range of data assets, research methodologies, advanced analytics, and deep domain expertise, generating quality insights for our clients.
LEARN MORETrusted advisor and partner to global healthcare organisations, solving the most significant business challenges through extensive healthcare expertise.
LEARN MOREOptimize commercial success by leveraging our comprehensive outsourced expertise to accelerate time-to-market.
LEARN MOREA single window solution provider to support pharmaco’s design, deploy technology and services that help increase access to medicine and improve treatment adherence.
LEARN MOREConnected Intelligence™, digital insights, data analytics and advanced technology to power smarter decision-making to enable better patient outcomes and improved business results.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific.
Learn MoreExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
Discover Insights"A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the Asia Pacific healthcare market.
Read The Latest Issue"Unlocking the Future of Consumer Health: A Special Focus on Senior Consumers
Learn MoreImproving human health requires innovative thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
Search JobsIf you were to read only one sentence, let it be this: healthcare funding or financing models require continuous attention and innovation in funding sources, pooling and strategic purchasing. Why is this? This blog will provide a window into the “Innovative Funding Models for High-Cost Non-Communicable Diseases (NCDs)” white paper and the new solutions disrupting healthcare financing.
As innovative treatments to address the unmet needs for high-cost chronic NCDs are developed, optimal patient outcomes become intrinsically linked to affordability. This brings a challenge for healthcare systems and traditional funding sources. Unless funding models are redesigned, there inevitably will be funding gaps affecting delivery and outcomes, therefore there is a need to complement and maximize resources in traditional public models.
Innovative funding or financing as a concept is not new; the term was developed in 2002 by the World Health Organization (WHO) to describe new financing from non-traditional sources and incentives. By nature, innovation requires an ongoing and active evolution and, as such, there is often little agreement about what constitutes innovative financing. Started in 2019, IQVIA and Roche in collaboration, have collected, reviewed and analyzed more than 100 innovative funding models, using a single framework with 5 archetypes: government funding schemes, blended finance, novel private insurance, multi-source crowdfunding, financial services.
Globally, there are multiple examples of innovative funding models success stories. For example, in China, Shuidi HuZhu (Shuidi Mutual Aid) is a multi-source crowdfunding example of private insurers and a technology platform coming together to reduce financial burden. Or in Nigeria, the government funding scheme “The Nigeria Cancer Health Fund” brings together public and private stakeholders to provide a funding pathway for low income patients to access cancer care. However, innovative funding models are not restricted to access, novel private insurance has successfully been used for diagnostic testing, as was the case in collaboration between AXA Partners Italia and Roche Italia to provide advanced genomic testing to policy holders. For more case studies or for an in-depth look at the 5 archetypes, click here to read to the full report.
Ultimately, the funding challenges posed by cancer and high-cost chronic NCDs are universal and unavoidable. There is an opportunity for diverse stakeholders — communities, governments, non-profit organizations, and the private sector — to collaborate and share knowledge to drive funding innovation, improve patient access to new scientific and technological advances, and improve financial protection. Furthermore, the COVID-19 pandemic has highlighted the importance of resilient health systems, both to society and to economic development. There is a global movement around the launch of innovative financing mechanisms and the potential for establishing non-traditional partnerships to create resilience and close the funding gap.
To read more about innovative funding models, including the full global innovative funding model landscape report and rare disease focus reports, click here.